Wilson I Gonsalves

List of Publications by Citations

370 papers	3,497 citations	30 h-index	48 g-index
400 ext. papers	4,603 ext. citations	3.9 avg, IF	5.01 L-index

#	Paper	IF	Citations
370	Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death. *Blood*, **2017**, 129, 2111-2119	2.2	181
369	Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria. *Blood Cancer Journal*, **2018**, 8, 59	7	115
368	Patient and tumor characteristics and BRAF and KRAS mutations in colon cancer, NCCTG/Alliance N0147. *Journal of the National Cancer Institute*, **2014**, 106,	9.7	109
367	Therapy for Relapsed Multiple Myeloma: Guidelines From the Mayo Stratification for Myeloma and Risk-Adapted Therapy. *Mayo Clinic Proceedings*, **2017**, 92, 578-598	6.4	88
366	Trends in survival of patients with primary plasma cell leukemia: a population-based analysis. *Blood*, **2014**, 124, 907-12	2.2	83
365	Diagnosis and Management of Waldenström Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016. *JAMA Oncology*, **2017**, 3, 1257-1265	13.4	82
364	The new oral anticoagulants in clinical practice. *Mayo Clinic Proceedings*, **2013**, 88, 495-511	6.4	79
363	Effects of volume and site of blood draw on blood culture results. *Journal of Clinical Microbiology*, **2009**, 47, 3482-5	9.7	71
362	Stem Cell Transplantation for Light Chain Amyloidosis: Decreased Early Mortality Over Time. *Journal of Clinical Oncology*, **2018**, 36, 1323-1329	2.2	68
361	Effect of palliative care services on the aggressiveness of end-of-life care in the Veteran's Affairs cancer population. *Journal of Palliative Medicine*, **2011**, 14, 1231-5	2.2	66
360	Quantification of clonal circulating plasma cells in relapsed multiple myeloma. *British Journal of Haematology*, **2014**, 167, 500-5	4.5	62
359	Daratumumab-based therapy in patients with heavily-pretreated AL amyloidosis. *Leukemia*, **2019**, 33, 531-536	10.7	60
358	Outcomes of patients with renal monoclonal immunoglobulin deposition disease. *American Journal of Hematology*, **2016**, 91, 1123-1128	7.1	52
357	Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement. *Bone Marrow Transplantation*, **2019**, 54, 353-367	4.4	51
356	Depth of organ response in AL amyloidosis is associated with improved survival: grading the organ response criteria. *Leukemia*, **2018**, 32, 2240-2249	10.7	49
355	Clinical presentation and outcomes of patients with type 1 monoclonal cryoglobulinemia. *American Journal of Hematology*, **2017**, 92, 668-673	7.1	46
354	Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myeloma. *Blood*, **2017**, 130, 1198-1204	2.2	46

353	MYD88 mutation status does not impact overall survival in Waldenström macroglobulinemia. *American Journal of Hematology*, **2018**, 93, 187-194	7.1	45
352	Presentation and Outcomes of Localized Immunoglobulin Light Chain Amyloidosis: The Mayo Clinic Experience. *Mayo Clinic Proceedings*, **2017**, 92, 908-917	6.4	43
351	Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenström macroglobulinemia. *Annals of Hematology*, **2018**, 97, 1417-1425	3	43
350	N-terminal fragment of the type-B natriuretic peptide (NT-proBNP) contributes to a simple new frailty score in patients with newly diagnosed multiple myeloma. *American Journal of Hematology*, **2016**, 91, 1129-1134	7.1	42
349	The prognostic value of multiparametric flow cytometry in AL amyloidosis at diagnosis and at the end of first-line treatment. *Blood*, **2017**, 129, 82-87	2.2	41
348	Combination therapy incorporating Bcl-2 inhibition with Venetoclax for the treatment of refractory primary plasma cell leukemia with t (11;14). *European Journal of Haematology*, **2018**, 100, 215-217	3.8	40
347	Long-term outcome of patients with POEMS syndrome: An update of the Mayo Clinic experience. *American Journal of Hematology*, **2016**, 91, 585-9	7.1	40
346	Revised diagnostic criteria for plasma cell leukemia: results of a Mayo Clinic study with comparison of outcomes to multiple myeloma. *Blood Cancer Journal*, **2018**, 8, 116	7	38
345	Induction therapy pre-autologous stem cell transplantation in immunoglobulin light chain amyloidosis: a retrospective evaluation. *American Journal of Hematology*, **2016**, 91, 984-8	7.1	37
344	Carnitine Palmitoyltransferase 1A Has a Lysine Succinyltransferase Activity. *Cell Reports*, **2018**, 22, 1365-1373	8.3	36
343	Lymphoplasmacytic Lymphoma With a Non-IgM Paraprotein Shows Clinical and Pathologic Heterogeneity and May Harbor MYD88 L265P Mutations. *American Journal of Clinical Pathology*, **2016**, 145, 843-51	1.9	33
342	A Modern Primer on Light Chain Amyloidosis in 592 Patients With Mass Spectrometry-Verified Typing. *Mayo Clinic Proceedings*, **2019**, 94, 472-483	6.4	33
341	Kidney Involvement of Patients with Waldenström Macroglobulinemia and Other IgM-Producing B Cell Lymphoproliferative Disorders. *Clinical Journal of the American Society of Nephrology: CJASN*, **2018**, 13, 1037-1046	6.9	32
340	Beta-blockers improve survival outcomes in patients with multiple myeloma: a retrospective evaluation. *American Journal of Hematology*, **2017**, 92, 50-55	7.1	30
339	Systemic Immunoglobulin Light Chain Amyloidosis-Associated Myopathy: Presentation, Diagnostic Pitfalls, and Outcome. *Mayo Clinic Proceedings*, **2016**, 91, 1354-1361	6.4	30
338	Optimizing deep response assessment for AL amyloidosis using involved free light chain level at end of therapy: failure of the serum free light chain ratio. *Leukemia*, **2019**, 33, 527-531	10.7	30
337	Efficacy of VDT PACE-like regimens in treatment of relapsed/refractory multiple myeloma. *American Journal of Hematology*, **2018**, 93, 179-186	7.1	29
336	Myelomatous Involvement of the Central Nervous System. *Clinical Lymphoma, Myeloma and Leukemia*, **2016**, 16, 644-654	2	29

335	Association between race and survival of patients with non--small-cell lung cancer in the United States veterans affairs population. *Clinical Lung Cancer*, **2014**, 15, 152-8	4.9	28
334	Overuse of organ biopsies in immunoglobulin light chain amyloidosis (AL): the consequence of failure of early recognition. *Annals of Medicine*, **2017**, 49, 545-551	1.5	27
333	Impact of minimal residual negativity using next generation flow cytometry on outcomes in light chain amyloidosis. *American Journal of Hematology*, **2020**, 95, 497-502	7.1	27
332	Targeted anti-cancer therapy in the elderly. *Critical Reviews in Oncology/Hematology*, **2011**, 78, 227-42	7	27
331	Ten-year survivors in AL amyloidosis: characteristics and treatment pattern. *British Journal of Haematology*, **2019**, 187, 588-594	4.5	26
330	Fifteen year overall survival rates after autologous stem cell transplantation for AL amyloidosis. *American Journal of Hematology*, **2019**, 94, 1020-1026	7.1	25
329	Pomalidomide, Bortezomib and Dexamethasone (PVD) for Patients with Relapsed Lenalidomide Refractory Multiple Myeloma (MM). *Blood*, **2014**, 124, 304-304	2.2	24
328	Glutamine-derived 2-hydroxyglutarate is associated with disease progression in plasma cell malignancies. *JCI Insight*, **2018**, 3,	9.9	23
327	Ibrutinib monotherapy outside of clinical trial setting in Waldenström macroglobulinaemia: practice patterns, toxicities and outcomes. *British Journal of Haematology*, **2020**, 188, 394-403	4.5	23
326	Histone deacetylase inhibition in combination with MEK or BCL-2 inhibition in multiple myeloma. *Haematologica*, **2019**, 104, 2061-2074	6.6	22
325	Natural history of multiple myeloma with de novo del(17p). *Blood Cancer Journal*, **2019**, 9, 32	7	22
324	Venetoclax for the treatment of translocation (11;14) AL amyloidosis. *Blood Cancer Journal*, **2020**, 10, 55	7	22
323	Efficacy of daratumumab-based therapies in patients with relapsed, refractory multiple myeloma treated outside of clinical trials. *American Journal of Hematology*, **2017**, 92, 1146-1155	7.1	22
322	Continued improvement in survival in multiple myeloma (MM) including high-risk patients.. *Journal of Clinical Oncology*, **2019**, 37, 8039-8039	2.2	22
321	IgM AL amyloidosis: delineating disease biology and outcomes with clinical, genomic and bone marrow morphological features. *Leukemia*, **2020**, 34, 1373-1382	10.7	22
320	The impact of dialysis on the survival of patients with immunoglobulin light chain (AL) amyloidosis undergoing autologous stem cell transplantation. *Nephrology Dialysis Transplantation*, **2016**, 31, 1284-9	4.3	21
319	Survival impact of achieving minimal residual negativity by multi-parametric flow cytometry in AL amyloidosis. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2020**, 27, 13-16	2.7	21
318	Sarcoidosis presenting with pancytopenia. *American Journal of Medicine*, **2014**, 127, e9-10	2.4	20

317	Impact of acquired del(17p) in multiple myeloma. *Blood Advances*, **2019**, 3, 1930-1938	7.8	20
316	Bone marrow plasma cells 20% or greater discriminate presentation, response, and survival in AL amyloidosis. *Leukemia*, **2020**, 34, 1135-1143	10.7	19
315	Clinical Features and Treatment Outcomes of Patients With Necrobiotic Xanthogranuloma Associated With Monoclonal Gammopathies. *Clinical Lymphoma, Myeloma and Leukemia*, **2016**, 16, 447-52	2	19
314	Treatment patterns and outcome following initial relapse or refractory disease in patients with systemic light chain amyloidosis. *American Journal of Hematology*, **2017**, 92, 549-554	7.1	18
313	Blood mass spectrometry detects residual disease better than standard techniques in light-chain amyloidosis. *Blood Cancer Journal*, **2020**, 10, 20	7	18
312	Prognostic significance of interphase FISH in monoclonal gammopathy of undetermined significance. *Leukemia*, **2018**, 32, 1811-1815	10.7	18
311	Implications of continued response after autologous stem cell transplantation for multiple myeloma. *Blood*, **2013**, 122, 1746-9	2.2	18
310	Impact of MYD88 mutation status on histological transformation of Waldenstrm Macroglobulinemia. *American Journal of Hematology*, **2020**, 95, 274-281	7.1	18
309	Overall survival of transplant eligible patients with newly diagnosed multiple myeloma: comparative effectiveness analysis of modern induction regimens on outcome. *Blood Cancer Journal*, **2018**, 8, 125	7	17
308	Plasma cell proliferative index is an independent predictor of progression in smoldering multiple myeloma. *Blood Advances*, **2018**, 2, 3149-3154	7.8	17
307	Role of chemotherapy in the very elderly patients with metastatic pancreatic cancer A Veterans Affairs Cancer Registry analysis. *Journal of Geriatric Oncology*, **2011**, 2, 209-214	3.6	16
306	Enhancing the R-ISS classification of newly diagnosed multiple myeloma by quantifying circulating clonal plasma cells. *American Journal of Hematology*, **2020**, 95, 310-315	7.1	16
305	Limiting early mortality: Do's and don'ts in the management of patients with newly diagnosed multiple myeloma. *American Journal of Hematology*, **2016**, 91, 101-8	7.1	16
304	Primary systemic amyloidosis in patients with Waldenstrm macroglobulinemia. *Leukemia*, **2019**, 33, 790-794	10.7	16
303	Light chain type predicts organ involvement and survival in AL amyloidosis patients receiving stem cell transplantation. *Blood Advances*, **2018**, 2, 769-776	7.8	16
302	Comparative analysis of staging systems in AL amyloidosis. *Leukemia*, **2019**, 33, 811-814	10.7	15
301	Predictors of symptomatic hyperviscosity in Waldenstrm macroglobulinemia. *American Journal of Hematology*, **2018**, 93, 1384-1393	7.1	15
300	Delineation of the timing of second-line therapy post-autologous stem cell transplant in patients with AL amyloidosis. *Blood*, **2017**, 130, 1578-1584	2.2	15

299	Outcomes with early response to first-line treatment in patients with newly diagnosed multiple myeloma. *Blood Advances*, **2019**, 3, 744-750	7.8	15
298	Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era. *Leukemia*, **2020**, 34, 3338-3347	10.7	15
297	Utility and prognostic value of F-FDG positron emission tomography-computed tomography scans in patients with newly diagnosed multiple myeloma. *American Journal of Hematology*, **2018**, 93, 1518-1523	7.1	15
296	Elevation of serum lactate dehydrogenase in AL amyloidosis reflects tissue damage and is an adverse prognostic marker in patients not eligible for stem cell transplantation. *British Journal of Haematology*, **2017**, 178, 888-895	4.5	14
295	Prognostic Significance of Holter Monitor Findings in Patients With Light Chain Amyloidosis. *Mayo Clinic Proceedings*, **2019**, 94, 455-464	6.4	13
294	The prognostic significance of CD45 expression by clonal bone marrow plasma cells in patients with newly diagnosed multiple myeloma. *Leukemia Research*, **2016**, 44, 32-9	2.7	13
293	Monoclonal gammopathy plus positive amyloid biopsy does not always equal AL amyloidosis. *American Journal of Hematology*, **2019**, 94, E141-E143	7.1	13
292	Bortezomib, lenalidomide, and dexamethasone (VRd) followed by autologous stem cell transplant for multiple myeloma. *Blood Cancer Journal*, **2018**, 8, 106	7	13
291	Prognostic Significance of Stringent Complete Response after Stem Cell Transplantation in Immunoglobulin Light Chain Amyloidosis. *Biology of Blood and Marrow Transplantation*, **2018**, 24, 2360-2364	4.7	13
290	Long-term outcomes of IMiD-based trials in patients with immunoglobulin light-chain amyloidosis: a pooled analysis. *Blood Cancer Journal*, **2020**, 10, 4	7	12
289	Analysis of Clinical Factors and Outcomes Associated with Nonuse of Collected Peripheral Blood Stem Cells for Autologous Stem Cell Transplants in Transplant-Eligible Patients with Multiple Myeloma. *Biology of Blood and Marrow Transplantation*, **2018**, 24, 2127-2132	4.7	12
288	Safety Outcomes for Autologous Stem Cell Transplant in Multiple Myeloma. *Mayo Clinic Proceedings*, **2018**, 93, 56-58	6.4	12
287	Dexamethasone, rituximab and cyclophosphamide for relapsed and/or refractory and treatment-naïve patients with Waldenstrom macroglobulinemia. *British Journal of Haematology*, **2017**, 179, 98-105	4.5	12
286	Phase 2 Trial of Daratumumab, Ixazomib, Lenalidomide and Modified Dose Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma. *Blood*, **2019**, 134, 864-864	2.2	12
285	Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma. *Blood Cancer Journal*, **2018**, 8, 70	7	11
284	The use of novel agents in multiple myeloma patients with hepatic impairment. *Future Oncology*, **2015**, 11, 501-10	3.6	11
283	Autologous Stem Cell Transplant for IgM-Associated Amyloid Light-Chain Amyloidosis. *Biology of Blood and Marrow Transplantation*, **2019**, 25, e108-e111	4.7	11
282	Relapse after complete response in newly diagnosed multiple myeloma: implications of duration of response and patterns of relapse. *Leukemia*, **2019**, 33, 730-738	10.7	11

281	Prevalence and survival of smouldering Waldenström macroglobulinaemia in the United States. *British Journal of Haematology*, **2019**, 184, 1014-1017	4.5	11
280	Hematology patient reported symptom screen to assess quality of life for AL amyloidosis. *American Journal of Hematology*, **2017**, 92, 435-440	7.1	10
279	Clinical features, laboratory characteristics and outcomes of patients with renal versus cardiac light chain amyloidosis. *British Journal of Haematology*, **2019**, 185, 701-707	4.5	10
278	Bone marrow dendritic cell aggregates associate with systemic immune dysregulation in chronic myelomonocytic leukemia. *Blood Advances*, **2020**, 4, 5425-5430	7.8	10
277	Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage. *Blood Cancer Journal*, **2021**, 11, 192	7	10
276	Revisiting complete response in light chain amyloidosis. *Leukemia*, **2020**, 34, 1472-1475	10.7	10
275	Refining amyloid complete hematological response: Quantitative serum free light chains superior to ratio. *American Journal of Hematology*, **2020**, 95, 1280-1287	7.1	10
274	Phase 1 Trial of MLN0128 (Sapanisertib) and CB-839 HCl (Telaglenastat) in Patients With Advanced NSCLC (NCI 10327): Rationale and Study Design. *Clinical Lung Cancer*, **2021**, 22, 67-70	4.9	10
273	Sex-based disparities in venous thromboembolism outcomes: A National Inpatient Sample (NIS)-based analysis. *Vascular Medicine*, **2017**, 22, 121-127	3.3	9
272	Treatment approaches and outcomes in plasmacytomas: analysis using a national dataset. *Leukemia* , **2018**, 32, 1414-1420	10.7	9
271	Impact of duration of induction therapy on survival in newly diagnosed multiple myeloma patients undergoing upfront autologous stem cell transplantation. *British Journal of Haematology*, **2018**, 182, 71-77	4.5	9
270	Impact of involved free light chain (FLC) levels in patients achieving normal FLC ratio after initial therapy in light chain amyloidosis (AL). *American Journal of Hematology*, **2018**, 93, 17-22	7.1	9
269	Impact of consolidation therapy post autologous stem cell transplant in patients with light chain amyloidosis. *American Journal of Hematology*, **2019**, 94, 1066-1071	7.1	9
268	Implications of detecting serum monoclonal protein by MASS-fix following stem cell transplantation in multiple myeloma. *British Journal of Haematology*, **2021**, 193, 380-385	4.5	9
267	Peripheral blood biomarkers of early immune reconstitution in newly diagnosed multiple myeloma. *American Journal of Hematology*, **2019**, 94, 306-311	7.1	9
266	Substratification of patients with newly diagnosed standard-risk multiple myeloma. *British Journal of Haematology*, **2019**, 185, 254-260	4.5	8
265	Plasma cell proliferative index predicts outcome in immunoglobulin light chain amyloidosis treated with stem cell transplantation. *Haematologica*, **2018**, 103, 1229-1234	6.6	8
264	Time to plateau as a predictor of survival in newly diagnosed multiple myeloma. *American Journal of Hematology*, **2018**, 93, 889-894	7.1	8

263	Visual loss in early-stage chronic lymphocytic leukemia. *Journal of Clinical Oncology*, **2013**, 31, e280-2	2.2	8
262	Granulomatous inflammation detected by endobronchial ultrasound-guided transbronchial needle aspiration in patients with a concurrent diagnosis of cancer: a clinical conundrum. *Journal of Bronchology and Interventional Pulmonology*, **2012**, 19, 176-81	1.8	8
261	Phase 2 Trial of Ixazomib, Lenalidomide, Dexamethasone and Daratumumab in Patients with Newly Diagnosed Multiple Myeloma. *Blood*, **2018**, 132, 304-304	2.2	8
260	MASS-FIX for the detection of monoclonal proteins and light chain N-glycosylation in routine clinical practice: a cross-sectional study of 6315 patients. *Blood Cancer Journal*, **2021**, 11, 50	7	8
259	Treatment of AL Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement 2020 Update. *Mayo Clinic Proceedings*, **2021**, 96, 1546-1577	6.4	8
258	Metabolomic and Lipidomic Profiling of Bone Marrow Plasma Differentiates Patients with Monoclonal Gammopathy of Undetermined Significance from Multiple Myeloma. *Scientific Reports*, **2020**, 10, 10250	4.9	7
257	Comparable outcomes using propylene glycol-free melphalan for autologous stem cell transplantation in multiple myeloma. *Bone Marrow Transplantation*, **2019**, 54, 587-594	4.4	7
256	The next generation of novel therapies for the management of relapsed multiple myeloma. *Future Oncology*, **2017**, 13, 63-75	3.6	7
255	Natural history of amyloidosis isolated to fat and bone marrow aspirate. *British Journal of Haematology*, **2017**, 179, 170-172	4.5	7
254	Metaphase cytogenetics and plasma cell proliferation index for risk stratification in newly diagnosed multiple myeloma. *Blood Advances*, **2020**, 4, 2236-2244	7.8	7
253	Impact of prior diagnosis of monoclonal gammopathy on outcomes in newly diagnosed multiple myeloma. *Leukemia*, **2019**, 33, 1273-1277	10.7	7
252	The impact of re-induction prior to salvage autologous stem cell transplantation in multiple myeloma. *Bone Marrow Transplantation*, **2019**, 54, 2039-2050	4.4	6
251	Outcomes of Patients with Light Chain Amyloidosis Who Had Autologous Stem Cell Transplantation with 3 or More Organs Involved. *Biology of Blood and Marrow Transplantation*, **2019**, 25, 1520-1525	4.7	6
250	Prognostic value of minimal residual disease and polyclonal plasma cells in myeloma patients achieving a complete response to therapy. *American Journal of Hematology*, **2019**, 94, 751-756	7.1	6
249	In vivo assessment of glutamine anaplerosis into the TCA cycle in human pre-malignant and malignant clonal plasma cells. *Cancer & Metabolism*, **2020**, 8, 29	5.4	6
248	Utilizing multiparametric flow cytometry in the diagnosis of patients with primary plasma cell leukemia. *American Journal of Hematology*, **2020**, 95, 637-642	7.1	6
247	Prognostic Significance of Quantifying Circulating Plasma Cells in Multiple Myeloma. *Clinical Lymphoma, Myeloma and Leukemia*, **2014**, 14, S147	2	6
246	Rituximab-based maintenance therapy in Waldenstr□h macroglobulinemia: A case control study.. *Journal of Clinical Oncology*, **2019**, 37, 7559-7559	2.2	6

245	Hematopoietic score predicts outcomes in newly diagnosed multiple myeloma patients. *American Journal of Hematology*, **2020**, 95, 4-9	7.1	6
244	Venetoclax for the treatment of multiple myeloma: Outcomes outside of clinical trials. *American Journal of Hematology*, **2021**, 96, 1131-1136	7.1	6
243	Autologous stem cell transplantation in patients with AL amyloidosis with impaired renal function. *Bone Marrow Transplantation*, **2019**, 54, 1775-1779	4.4	5
242	Differences in engraftment with day-1 compared with day-2 melphalan prior to stem cell infusion in myeloma patients receiving autologous stem cell transplant. *Bone Marrow Transplantation*, **2020**, 55, 2132-2137	4.4	5
241	Prognostic significance of circulating plasma cells by multi-parametric flow cytometry in light chain amyloidosis. *Leukemia*, **2018**, 32, 1421-1426	10.7	5
240	Plasma cell proliferative index post-transplant is a powerful predictor of prognosis in myeloma patients failing to achieve a complete response. *Bone Marrow Transplantation*, **2019**, 54, 442-447	4.4	5
239	Presentation and Outcomes of Localized Amyloidosis: The Mayo Clinic Experience. *Blood*, **2015**, 126, 4197-4197	2.2	5
238	Efficacy of Carfilzomib (K), Pomalidomide (P), and Dexamethasone (d) in Heavily Pretreated Patients with Relapsed/ Refractory Multiple Myeloma (RRMM) in a Real World Setting. *Blood*, **2016**, 128, 3337-3337	2.2	5
237	Mortality trends in multiple myeloma after the introduction of novel therapies in the United States. *Leukemia*, **2021**,	10.7	5
236	Delayed neutrophil engraftment in patients receiving Daratumumab as part of their first induction regimen for multiple myeloma. *American Journal of Hematology*, **2020**, 95, E8-E10	7.1	5
235	Cytogenetic Features and Clinical Outcomes of Patients With Non-secretory Multiple Myeloma in the Era of Novel Agent Induction Therapy. *Clinical Lymphoma, Myeloma and Leukemia*, **2020**, 20, 53-56	2	5
234	Rapid assessment of hyperdiploidy in plasma cell disorders using a novel multi-parametric flow cytometry method. *American Journal of Hematology*, **2019**, 94, 424-430	7.1	5
233	Autologous stem cell transplantation for multiple myeloma patients aged ≥ 75 treated with novel agents. *Bone Marrow Transplantation*, **2021**, 56, 1144-1150	4.4	5
232	Disease outcomes and biomarkers of progression in smouldering Waldenström macroglobulinaemia. *British Journal of Haematology*, **2021**, 195, 210-216	4.5	5
231	Crystalglobulin-Induced Nephropathy and Keratopathy. *Kidney Medicine*, **2019**, 1, 71-74	2.8	4
230	Prognostic restaging at the time of second-line therapy in patients with AL amyloidosis. *Leukemia*, **2019**, 33, 1268-1272	10.7	4
229	The role of bone marrow biopsy in patients with plasma cell disorders: should all patients with a monoclonal protein be biopsied?. *Blood Cancer Journal*, **2020**, 10, 52	7	4
228	Impact of prior melphalan exposure on stem cell collection in light chain amyloidosis. *Bone Marrow Transplantation*, **2018**, 53, 326-333	4.4	4

227	Depth of organ response in AL amyloidosis is associated with improved survival: new proposed organ response criteria. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2019**, 26, 101-102	2.7	4
226	Early Mortality in Multiple Myeloma: Risk Factors and Impact on Population Outcomes. *Blood*, **2014**, 124, 1320-1320	2.2	4
225	Outcomes with rituximab plus bendamustine (R-Benda), dexamethasone, rituximab, cyclophosphamide (DRC), and bortezomib, dexamethasone, rituximab (BDR) as primary therapy in patients with Waldenstrom macroglobulinemia (WM).. *Journal of Clinical Oncology*, **2019**, 37, 7509-7509	2.2	4
224	Clinical Characteristics and Outcomes of Patients With Primary Plasma Cell Leukemia in the Era of Novel Agent Therapy. *Mayo Clinic Proceedings*, **2021**, 96, 677-687	6.4	4
223	Enzymatic activation of pyruvate kinase increases cytosolic oxaloacetate to inhibit the Warburg effect. *Nature Metabolism*, **2021**, 3, 954-968	14.6	4
222	Utility of serum free light chain ratio in response definition in patients with multiple myeloma. *Blood Advances*, **2020**, 4, 322-326	7.8	4
221	Disease monitoring with quantitative serum IgA levels provides a more reliable response assessment in multiple myeloma patients. *Leukemia*, **2021**, 35, 1428-1437	10.7	4
220	Defining Lymphoplasmacytic Lymphoma: Does MYD88L265P Define a Pathologically Distinct Entity Among Patients With an IgM Paraprotein and Bone Marrow-Based Low-Grade B-Cell Lymphomas With Plasmacytic Differentiation?. *American Journal of Clinical Pathology*, **2018**, 150, 168-176	1.9	4
219	Estimating the annual volume of hematologic cancer cases per hematologist-oncologist in the United States: are we treating rare cancers too rarely?. *Leukemia and Lymphoma*, **2017**, 58, 251-252	1.9	3
218	Immunoparesis in newly diagnosed AL amyloidosis is a marker for response and survival. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2017**, 24, 40-41	2.7	3
217	The prognostic significance of polyclonal bone marrow plasma cells in patients with relapsing multiple myeloma. *American Journal of Hematology*, **2017**, 92, E507-E512	7.1	3
216	Outcomes with early vs. deferred stem cell transplantation in light chain amyloidosis. *Bone Marrow Transplantation*, **2020**, 55, 1297-1304	4.4	3
215	Increased Bone Marrow Plasma-Cell Percentage Predicts Outcomes in Newly Diagnosed Multiple Myeloma Patients. *Clinical Lymphoma, Myeloma and Leukemia*, **2020**, 20, 596-601	2	3
214	Autologous Stem Cell Transplant for Immunoglobulin Light Chain Amyloidosis Patients Aged 70 to 75. *Biology of Blood and Marrow Transplantation*, **2018**, 24, 2157-2159	4.7	3
213	Comparison of different techniques to identify cardiac involvement in immunoglobulin light chain (AL) amyloidosis. *Blood Advances*, **2019**, 3, 1226-1229	7.8	3
212	Characteristics of long-term survivors with multiple myeloma: A National Cancer Data Base analysis. *Cancer*, **2019**, 125, 3574-3581	6.4	3
211	Daratumumab, Ixazomib, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma. *Blood*, **2020**, 136, 36-37	2.2	3
210	PET-CT Has Major Diagnostic Value in the Evaluation of Smoldering Multiple Myeloma. *Blood*, **2014**, 124, 3382-3382	2.2	3

209	Bendamustine and Rituximab Versus Dexamethasone, Rituximab and Cyclophosphamide in Patients with Waldenstrom Macroglobulinemia (WM). *Blood*, **2016**, 128, 2968-2968	2.2	3
208	Bortezomib Versus Non-Bortezomib Based Treatment for Transplant Ineligible Patients with Light Chain Amyloidosis. *Blood*, **2016**, 128, 3317-3317	2.2	3
207	Aurora kinase and FGFR3 inhibition results in significant apoptosis in molecular subgroups of multiple myeloma. *Oncotarget*, **2018**, 9, 34582-34594	3.3	3
206	Effect of Surgical Intervention on Survival of Patients With Clinical N2 Non-Small Cell Lung Cancer: A Veterans' Affairs Central Cancer Registry (VACCR) Database Analysis. *American Journal of Clinical Oncology: Cancer Clinical Trials*, **2016**, 39, 142-6	2.7	3
205	Safety and efficacy of propylene glycol-free melphalan as conditioning in patients with AL amyloidosis undergoing stem cell transplantation. *Bone Marrow Transplantation*, **2019**, 54, 1077-1081	4.4	3
204	Characterization and prognostic implication of delayed complete response in AL amyloidosis. *European Journal of Haematology*, **2021**, 106, 354-361	3.8	3
203	Outcomes with different administration schedules of bortezomib in bortezomib, lenalidomide and dexamethasone (VRd) as first-line therapy in multiple myeloma. *American Journal of Hematology*, **2021**, 96, 330-337	7.1	3
202	Prognostic restaging after treatment initiation in patients with AL amyloidosis. *Blood Advances*, **2021**, 5, 1029-1036	7.8	3
201	Coagulation Abnormalities in Light Chain Amyloidosis. *Mayo Clinic Proceedings*, **2021**, 96, 377-387	6.4	3
200	Comparison of the current renal staging, progression and response criteria to predict renal survival in AL amyloidosis using a Mayo cohort. *American Journal of Hematology*, **2021**, 96, 446-454	7.1	3
199	Development of thrombocytopenia during first-line treatment and survival outcomes in newly diagnosed multiple myeloma. *Leukemia and Lymphoma*, **2019**, 60, 2960-2967	1.9	2
198	Reductive amination of Ketoglutarate in metabolite extracts results in glutamate overestimation. *Journal of Chromatography A*, **2020**, 1623, 461169	4.5	2
197	Prognostic Role of Beta-2 Microglobulin in Patients with Light Chain Amyloidosis Treated with Autologous Stem Cell Transplantation. *Biology of Blood and Marrow Transplantation*, **2020**, 26, 1402-1405	4.7	2
196	Of lions, shar-pei, and doughnuts: a tale retold. *Blood*, **2020**, 135, 1074-1076	2.2	2
195	Epstein-barr virus infection in an elderly nonimmunocompromised adult successfully treated with rituximab. *Case Reports in Hematology*, **2014**, 2014, 641483	0.7	2
194	Chronic Eosinophilic Leukemia-Not Otherwise Specified (NOS) in the Background of a Large Cell Lymphoma. *Case Reports in Hematology*, **2013**, 2013, 458303	0.7	2
193	Tracking daratumumab clearance using mass spectrometry: implications on M protein monitoring and reusing daratumumab.. *Leukemia*, **2022**,	10.7	2
192	Melflufen for multiple myeloma: a promise unfulfilled?. *Lancet Haematology,the*, **2022**,	14.6	2

191	Prognostic Implications of Serum Monoclonal Protein Positivity By Mass-Fix in Bone Marrow Minimal Residual Disease Negative (MRD-) Patients with Multiple Myeloma. *Blood*, **2019**, 134, 4386-4386	2.2	2
190	Phase 2 Trial of Ixazomib, Cyclophosphamide and Dexamethasone for Treatment of Previously Untreated Light Chain Amyloidosis. *Blood*, **2020**, 136, 52-53	2.2	2
189	Continued Improvement in Survival of Patients with Newly Diagnosed Multiple Myeloma (MM). *Blood*, **2020**, 136, 30-31	2.2	2
188	Sequential Comparison of Conventional Serum Immunofixation (IFE) to Mass Spectrometry-Based Assessment (MASS FIX) in Patients with Multiple Myeloma (MM). *Blood*, **2020**, 136, 12-13	2.2	2
187	Dexamethasone, Rituximab and Cyclophosphamide (DRC) As Salvage Therapy for Waldenstrom Macroglobulinemia. *Blood*, **2016**, 128, 2972-2972	2.2	2
186	What are patients biggest concerns? A patient reported outcome case-management system.. *Journal of Clinical Oncology*, **2017**, 35, 6572-6572	2.2	2
185	Daratumumab-based therapies in patients with AL amyloidosis.. *Journal of Clinical Oncology*, **2018**, 36, 8053-8053	2.2	2
184	Clinical and cytogenetic features of nonsecretory multiple myeloma (NSMM) in the era of novel agent induction therapy: The Mayo Clinic experience.. *Journal of Clinical Oncology*, **2019**, 37, e19519-e19519	2.2	2
183	"Real-Life" Data of the Efficacy and Safety of Belantamab Mafodotin in Relapsed Multiple Myeloma- the Mayo Clinic Experience. *Blood*, **2021**, 138, 1639-1639	2.2	2
182	Plasma Cell Proliferative Index Is an Independent Predictor of Progression in Smoldering Multiple Myeloma. *Blood*, **2018**, 132, 3160-3160	2.2	2
181	Characteristics and outcome of patients with MYD88 wild-type Waldenstrm Macroglobulinemia.. *Journal of Clinical Oncology*, **2020**, 38, 8550-8550	2.2	2
180	Assessment of fixed-duration therapies for treatment-nave Waldenstrm macroglobulinemia. *American Journal of Hematology*, **2021**, 96, 945-953	7.1	2
179	The Impact of Socioeconomic Risk Factors on the Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma: A Cross-analysis of a Population-based Registry and a Tertiary Care Center. *Clinical Lymphoma, Myeloma and Leukemia*, **2021**, 21, 451-460.e2	2	2
178	Second Stem Cell Transplantation for Relapsed Refractory Light Chain (AL) Amyloidosis. *Transplantation and Cellular Therapy*, **2021**, 27, 589.e1-589.e6		2
177	Depth of response prior to autologous stem cell transplantation predicts survival in light chain amyloidosis. *Bone Marrow Transplantation*, **2021**, 56, 928-935	4.4	2
176	Clinical correlates and prognostic impact of clonal hematopoiesis in multiple myeloma patients receiving post-autologous stem cell transplantation lenalidomide maintenance therapy. *American Journal of Hematology*, **2021**, 96, E157-E162	7.1	2
175	Correlation between urine ACR and 24-h proteinuria in a real-world cohort of systemic AL amyloidosis patients. *Blood Cancer Journal*, **2020**, 10, 124	7	1
174	Baseline immune dysregulation in autologous stem cell transplant recipients is associated with a 'graft versus host'-like syndrome and poor outcomes. *Bone Marrow Transplantation*, **2020**, 55, 1879-1881	4.4	1

173	Serum free light chain measurements to reduce 24-h urine monitoring in patients with multiple myeloma with measurable urine monoclonal protein. *American Journal of Hematology*, **2018**, 93, 1207-1210	7.1	1
172	59-Year-Old Man With Fatigue, Weight Loss, and Hepatomegaly. *Mayo Clinic Proceedings*, **2018**, 93, 1525-1529	6.4	1
171	Gallbladder cancer-associated thrombotic microangiopathy. *Future Oncology*, **2013**, 9, 1711-5	3.6	1
170	POEMS syndrome: An elusive diagnosis. *American Journal of Hematology*, **2017**, 92, 1269-1270	7.1	1
169	Predictors of early treatment failure following initial therapy for systemic immunoglobulin light-chain amyloidosis. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2017**, 24, 183-188	2.7	1
168	Efficacy of Daratumumab (Dara)-Based Regimens for the Treatment of Plasma Cell Leukemia (PCL). *Blood*, **2020**, 136, 29-30	2.2	1
167	Utilizing Multiparametric Flow Cytometry to Identify Patients with Primary Plasma Cell Leukemia at Diagnosis. *Blood*, **2019**, 134, 4334-4334	2.2	1
166	Phase 2 Trial of LDE225 and Lenalidomide Maintenance Post Autologous Stem Cell Transplant for Multiple Myeloma. *Blood*, **2019**, 134, 1905-1905	2.2	1
165	Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon Beta, in Patients with Relapsed or Refractory Multiple Myeloma (MM), Acute Myeloid Leukemia (AML), and T-Cell Neoplasms (TCL). *Blood*, **2020**, 136, 7-8	2.2	1
164	Presence of a Measurable M-Spike before Autologous Stem Cell Transplantation Is Associated with Shorter Survival in Patients with Light Chain Amyloidosis. *Blood*, **2020**, 136, 22-23	2.2	1
163	Necrobiotic Xanthogranuloma (NXG) Associated with Monoclonal Gammopathies (MG): Clinical Features and Treatment Outcomes. *Blood*, **2015**, 126, 1830-1830	2.2	1
162	Predictors of Early Relapse Following Initial Therapy for Systemic Immunoglobulin Light Chain Amyloidosis. *Blood*, **2016**, 128, 2082-2082	2.2	1
161	Clinical Features and Outcomes of Plasmacytoma in the United States: Analysis Using the National Cancer Data Base. *Blood*, **2016**, 128, 3249-3249	2.2	1
160	Clinical Presentation and Outcomes of Patients with Light Chain Amyloidosis Who Have Non-Evaluable Free Light Chains at Diagnosis. *Blood*, **2016**, 128, 3272-3272	2.2	1
159	Practice Patterns of Re-Initiation of Therapy at Time of Relapse or Progression Post- Autologous Stem Cell Transplant (ASCT) Among Patients with AL Amyloidosis. *Blood*, **2016**, 128, 3444-3444	2.2	1
158	Effect of Standard Dose Versus Risk Adapted Melphalan Conditioning on Outcomes in Systemic AL Amyloidosis Patients Undergoing Frontline Autologous Stem Cell Transplant Based on Revised Mayo Stage. *Blood*, **2016**, 128, 4627-4627	2.2	1
157	Evolving changes in M-protein (M), quantitative involved immunoglobulin (Ig), and hemoglobin (Hb) to identify patients (pts) with ultra high-risk smoldering multiple myeloma (UHR-SMM).. *Journal of Clinical Oncology*, **2016**, 34, 8004-8004	2.2	1
156	Quantification of circulating clonal plasma cells (cPCs) via multiparametric flow cytometry (MFC) to identify patients with smoldering multiple myeloma (SMM) at high risk of progression.. *Journal of Clinical Oncology*, **2016**, 34, 8015-8015	2.2	1

155	Daratumumab-based combination therapies (DCT) in heavily-pretreated patients (pts) with relapsed and/or refractory multiple myeloma (RRMM).. *Journal of Clinical Oncology*, **2017**, 35, 8038-8038	2.2	1
154	Factors predicting organ response in light chain amyloidosis (AL).. *Journal of Clinical Oncology*, **2017**, 35, 8048-8048	2.2	1
153	Ixazomib, lenalidomide, and dexamethasone for patients with POEMS syndrome.. *Journal of Clinical Oncology*, **2019**, 37, 8019-8019	2.2	1
152	Assessing the prognostic utility of smoldering multiple myeloma risk stratification scores applied serially post diagnosis. *Blood Cancer Journal*, **2021**, 11, 186	7	1
151	Characteristics and risk factors for thrombosis in POEMS syndrome: A retrospective evaluation of 230 patients. *American Journal of Hematology*, **2021**,	7.1	1
150	Trial in Progress: Phase I Open-Label Study of Metformin and Nelfinavir in Combination with Bortezomib in Patients with Relapsed and/or Refractory Multiple Myeloma. *Blood*, **2021**, 138, 2735-2735	2.2	1
149	Single Cell Transcriptome Profile of Myeloma and Immune Cell Characteristics in Patients with Durable Response Post CART. *Blood*, **2021**, 138, 3838-3838	2.2	1
148	Outcomes of triple class (proteasome inhibitor, IMiDs and monoclonal antibody) refractory patients with multiple myeloma. *Leukemia*, **2021**,	10.7	1
147	Ibrutinib Therapy in Patients with Waldenstrom Macroglobulinemia: Outcomes Outside of Clinical Trial Setting. *Blood*, **2018**, 132, 1606-1606	2.2	1
146	Impact of MYD88L265P mutation Status on Histological Transformation of Waldenstrom Macroglobulinemia. *Blood*, **2018**, 132, 2884-2884	2.2	1
145	Prognosis of Patients with Waldenstrm Macroglobulinemia: A Simplified Model. *Blood*, **2018**, 132, 4152-4152	2.2	1
144	Upstaging the R-ISS classification of newly diagnosed multiple myeloma (NDMM) patients (pts) by quantifying circulating clonal plasma cells (cPCs) via multiparametric flow cytometry (MFC).. *Journal of Clinical Oncology*, **2019**, 37, 8031-8031	2.2	1
143	Trial in Progress: Phase I Dose-Escalation and Dose-Expansion Trial of a Novel Glutaminase Inhibitor (CB-839 HCl) in Combination with Carfilzomib and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma. *Blood*, **2019**, 134, 3160-3160	2.2	1
142	Clinical Outcomes and Cytogenetic Features of Primary Plasma Cell Leukemia (pPCL) in the Era of Novel Agent Induction Therapy. *Blood*, **2019**, 134, 5490-5490	2.2	1
141	Outcomes of patients with primary plasma cell leukemia (pPCL) in the era of novel agent therapy.. *Journal of Clinical Oncology*, **2020**, 38, e20510-e20510	2.2	1
140	Quality of life (QOL), financial burden, and perception of care in patients enrolled on clinical trials (CTs).. *Journal of Clinical Oncology*, **2020**, 38, e19112-e19112	2.2	1
139	Dexamethasone, rituximab and cyclophosphamide (DRC) in relapsed/refractory (R/R) and treatment naïve (TN) Waldenstrm macroglobulinemia (WM).. *Journal of Clinical Oncology*, **2016**, 34, 7552-7552	2.2	1
138	Implications and outcomes of MRD-negative multiple myeloma patients with immunofixation positivity. *American Journal of Hematology*, **2020**, 95, E60-E62	7.1	1

137	Colon perforation in multiple myeloma patients - A complication of high-dose steroid treatment. *Cancer Medicine*, **2020**, 9, 8895-8901	4.8	1
136	Predictors of short-term survival in Waldenstrm Macroglobulinemia. *Leukemia and Lymphoma*, **2020**, 61, 2975-2979	1.9	1
135	Chemotherapy-based stem cell mobilization in multiple myeloma patients treated with novel agents: The Mayo Clinic experience.. *Journal of Clinical Oncology*, **2021**, 39, e20000-e20000	2.2	1
134	Retroperitoneal involvement with light chain amyloidosis- case series and literature review. *Leukemia and Lymphoma*, **2021**, 62, 316-322	1.9	1
133	Current diagnosis, risk stratification and treatment paradigms in newly diagnosed multiple myeloma. *Cancer Treatment and Research Communications*, **2021**, 29, 100444	2	1
132	Increased fecal primary bile acids in multiple myeloma with engraftment syndrome diarrhea after stem cell transplant. *Bone Marrow Transplantation*, **2019**, 54, 1898-1907	4.4	0
131	Unmet Needs in AL Amyloidosis: Outcomes in the Modern Era Among the Highest Risk, Newly Diagnosed AL Amyloidosis Patients. *Blood*, **2020**, 136, 31-32	2.2	0
130	IgM Associated Light Chain (AL) Amyloidosis: Delineating Disease Biology with Clinical, Genomic and Bone Marrow Morphological Features. *Blood*, **2018**, 132, 4460-4460	2.2	0
129	MASS-FIX for the Diagnosis of Plasma Cell Disorders: A Single Institution Experience of 4118 Patients. *Blood*, **2020**, 136, 48-49	2.2	0
128	Outcomes Following Biochemical or Clinical Progression in Patients with Multiple Myeloma. *Blood*, **2021**, 138, 3760-3760	2.2	0
127	Ocular Toxicity of Commercially Available Belantamab Mafodotin in Patients with Advanced Multiple Myeloma. *Blood*, **2021**, 138, 2711-2711	2.2	0
126	Prognostic Impact of CD3 Count in Apheresis Collection in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplant. *Blood*, **2021**, 138, 3774-3774	2.2	0
125	Optimal Therapy for Relapsed AL Amyloidosis Post Autologous Stem Cell Transplant. *Blood*, **2019**, 134, 3171-3171	2.2	0
124	Sex-Based Disparities in Venous Thromboembolism Sociodemographics and Outcomes: A National Inpatient Sample (NIS)-Based Analysis. *Blood*, **2016**, 128, 5918-5918	2.2	0
123	Natural history of t(11;14) multiple myeloma (MM).. *Journal of Clinical Oncology*, **2017**, 35, 8014-8014	2.2	0
122	Efficacy of Daratumumab-Based Regimens for the Treatment of Plasma Cell Leukemia. *Clinical Lymphoma, Myeloma and Leukemia*, **2021**, 21, 355-360	2	0
121	Prognostic impact of posttransplant FDG PET/CT scan in multiple myeloma. *Blood Advances*, **2021**, 5, 2753-2759	7.8	0
120	Ageism in the t(11;14) Subtype of Multiple Myeloma. *Acta Haematologica*, **2021**, 144, 6-7	2.7	0

119	Prognostic value of NT-ProBNP and troponin T in patients with light chain amyloidosis and kidney dysfunction undergoing autologous stem cell transplantation. *Bone Marrow Transplantation*, **2021**, 56, 274-277	4.4	0
118	Outcomes of multiple myeloma patients with del 17p undergoing autologous stem cell transplantation. *American Journal of Hematology*, **2021**, 96, E35-E38	7.1	0
117	Use of beta blockers is associated with survival outcome of multiple myeloma patients treated with pomalidomide. *European Journal of Haematology*, **2021**, 106, 433-436	3.8	0
116	Amyloid arthropathy in smoldering myeloma: Do not take it lightly. *Leukemia Research Reports*, **2021**, 15, 100242	0.6	0
115	Treatment and outcome of newly diagnosed multiple myeloma patients > 75 years old: a retrospective analysis. *Leukemia and Lymphoma*, **2021**, 62, 3011-3018	1.9	0
114	The Efficacy and Safety of Chemotherapy-Based Stem Cell Mobilization in Multiple Myeloma Patients Who Are Poor Responders to Induction: The Mayo Clinic Experience. *Transplantation and Cellular Therapy*, **2021**, 27, 770.e1-770.e7		0
113	Treatment and outcomes of patients with light chain amyloidosis who received a second line of therapy post autologous stem cell transplantation.. *Blood Cancer Journal*, **2022**, 12, 59	7	0
112	Lack of a caregiver is associated with shorter survival in myeloma patients undergoing autologous stem cell transplantation.. *Leukemia and Lymphoma*, **2022**, 1-6	1.9	0
111	Drugs that affect blood coagulation, fibrinolysis, and hemostasis. *Side Effects of Drugs Annual*, **2014**, 35, 617-631	0.2	
110	Bortezomib-based combination regimens in myeloma: more is not necessarily better. *Leukemia and Lymphoma*, **2014**, 55, 1439-40	1.9	
109	Secondary Hemophagocytic Syndrome Associated with Richter's Transformation in Chronic Lymphocytic Leukemia. *Case Reports in Hematology*, **2014**, 2014, 287479	0.7	
108	Systemic amyloidosis masquerading as iron deficiency anemia. *Indian Journal of Gastroenterology*, **2012**, 31, 351-2	1.9	
107	A 49-year-old woman with acute respiratory failure. *Chest*, **2010**, 138, 224-7	5.3	
106	Comparison of Conventional Xrays with CT Based Approaches for Detection of Lytic Lesions in Multiple Myeloma. *Blood*, **2020**, 136, 27-28	2.2	
105	A Cross Sectional Evaluation of Light Chain N-Glycosylation By MASS-FIX in Plasma Cell Disorders. *Blood*, **2020**, 136, 44-45	2.2	
104	Prognostic Impact of PET Findings Post-Transplant in Multiple Myeloma. *Blood*, **2020**, 136, 15-16	2.2	
103	Treatments and Outcomes of Newly Diagnosed Multiple Myeloma Patients > 75 Years Old: A Retrospective Analysis. *Blood*, **2020**, 136, 14-15	2.2	
102	Prognostic Restaging after Treatment Initiation in Patients with AL Amyloidosis. *Blood*, **2020**, 136, 6-7	2.2	

101	Outcomes of Multiple Myeloma Patients with Del 17p Undergoing Autologous Stem Cell Transplantation. *Blood*, **2020**, 136, 21-22	2.2
100	A 3-Question Symptom Assessment Score Can Predict Outcomes in Newly Diagnosed Multiple Myeloma (MM). *Blood*, **2020**, 136, 21-22	2.2
99	Autologous Stem Cell Transplantation for Multiple Myeloma Patients Aged ≥ 75 Treated with Novel Agents. *Blood*, **2020**, 136, 12-13	2.2
98	Retroperitoneal Involvement of Light Chain Amyloidosis-Case Series and Literature Review. *Blood*, **2020**, 136, 37-38	2.2
97	Decreased Cardiac Ejection Fraction Is Associated with Worse Survival in Patients with Light Chain Amyloidosis Treated with Autologous Stem Cell Transplantation. *Blood*, **2020**, 136, 41-42	2.2
96	Waldenström Macroglobulinemia in the Very Elderly (≥ 75 years):Clinical Characteristics and Outcomes. *Blood*, **2020**, 136, 44-45	2.2
95	Waiting in line for cancer treatments?. *Gastrointestinal Cancer Research: GCR*, **2011**, 4, 147-9	
94	Tracking Daratumumab Clearance Using Mass Spectrometric Approaches: Implications on M Protein Monitoring and Reusing Daratumumab. *Blood*, **2021**, 138, 2707-2707	2.2
93	An Analysis of Virus Amplification and Antitumor Responses in T-Cell Lymphoma Patients Treated with Voyager-V1 (VSV-IFNβNIS). *Blood*, **2021**, 138, 1333-1333	2.2
92	Prognostic Role of IL-6 in POEMS Syndrome. *Blood*, **2021**, 138, 2700-2700	2.2
91	Monoclonal Proteinuria Predicts Progression Risk in Asymptomatic Multiple Myeloma with a Free Light Chain Ratio ≥100. *Blood*, **2021**, 138, 1617-1617	2.2
90	Disrupting the Reverse Warburg Effect As a Therapeutic Strategy in Multiple Myeloma. *Blood*, **2021**, 138, 2649-2649	2.2
89	Second Line Treatment Strategies in Multiple Myeloma: A Referral-Center Experience. *Blood*, **2021**, 138, 819-819	2.2
88	Amyloidosis Composite Response Score Incorporating the Depth of Organ Response. *Blood*, **2021**, 138, 3805-3805	2.2
87	Impact of Achieving an Early Complete Response in Multiple Myeloma and Predictors of Subsequent Outcome. *Blood*, **2021**, 138, 3773-3773	2.2
86	Prognostic Factors for Early (<2 years) and Late (>5 years) Relapse in Multiple Myeloma-Pivotal Role of Cytogenetic Changes. *Blood*, **2021**, 138, 3761-3761	2.2
85	The Prognostic Utility of Serial MASS-FIX in Multiple Myeloma. *Blood*, **2021**, 138, 1619-1619	2.2
84	Assessing the Prognostic Utility of the Mayo 2018 and IMWG 2020 Smoldering Multiple Myeloma Risk Stratification Scores When Applied Post Diagnosis. *Blood*, **2021**, 138, 543-543	2.2

83	Factors Associated with Renal Impairment at Diagnosis in Multiple Myeloma with Survival Trends over Last Two Decades. *Blood*, **2021**, 138, 1630-1630	2.2
82	Mortality Trends in Multiple Myeloma after the Introduction of Novel Therapies in the United States. *Blood*, **2021**, 138, 119-119	2.2
81	The Impact of the Central Carbon Energy Metabolism Transcriptome in the Pathogenesis and Outcomes of Multiple Myeloma. *Blood*, **2021**, 138, 2650-2650	2.2
80	Supportive care in multiple myeloma: Current practices and advances. *Cancer Treatment and Research Communications*, **2021**, 29, 100476	2
79	Utility and prognostic value of 18F-FDG PET/CT scan in patients with newly diagnosed multiple myeloma.. *Journal of Clinical Oncology*, **2018**, 36, 8023-8023	2.2
78	Natural history of delp53 multiple myeloma.. *Journal of Clinical Oncology*, **2018**, 36, e20017-e20017	2.2
77	Duration of complete response (DurCR) impacts overall survival (OS) in multiple myeloma (MM).. *Journal of Clinical Oncology*, **2018**, 36, 8045-8045	2.2
76	Prognostic value of minimal residual disease and polyclonal plasma cells in myeloma patients achieving a complete response to therapy.. *Journal of Clinical Oncology*, **2018**, 36, 8030-8030	2.2
75	Long-Term Survivorship with Active Multiple Myeloma. *Blood*, **2018**, 132, 1912-1912	2.2
74	Comparative Analysis of Staging Systems in AL Amyloidosis. *Blood*, **2018**, 132, 3228-3228	2.2
73	Early Prediction of Treatment Response in Newly Diagnosed Multiple Myeloma. *Blood*, **2018**, 132, 3159-3159	2.2
72	Prognostic Significance of Early Immune Reconstitution in Newly Diagnosed Multiple Myeloma. *Blood*, **2018**, 132, 3158-3158	2.2
71	Impact of Acquired Del(17p) in Patients with Multiple Myeloma. *Blood*, **2018**, 132, 4449-4449	2.2
70	Bortezomib, Lenalidomide and Dexamethasone (VRD) Followed By Autologous Stem Cell Transplant for Newly Diagnosed Multiple Myeloma; The Mayo Clinic Experience. *Blood*, **2018**, 132, 2147-2147	2.2
69	Long-Term AL Amyloidosis Survivors Among Non-Selected Referral Population. *Blood*, **2018**, 132, 3226-3226	2.2
68	Salvage Autologous Stem Cell Transplantation in Multiple Myeloma: Investigating the Impact of Pre-Transplant Therapy. *Blood*, **2018**, 132, 4613-4613	2.2
67	Expected Survival in Patients with Smoldering Multiple Myeloma and Multiple Myeloma. *Blood*, **2018**, 132, 4497-4497	2.2
66	Mass Spectrometry to Measure Response in Immunoglobulin Light Chain Amyloidosis (AL). *Blood*, **2018**, 132, 4502-4502	2.2

65	Development of Thrombocytopenia and Survival Outcomes in Newly Diagnosed Multiple Myeloma. *Blood*, **2018**, 132, 1902-1902	2.2
64	Prognostic Restaging at the Time of 2nd-Line Therapy in Patients with AL Amyloidosis. *Blood*, **2018**, 132, 5594-5594	2.2
63	Optimizing Deep Response Assessment for AL Amyloidosis Using Involved Free Light Chain Level at End of Therapy. *Blood*, **2018**, 132, 3227-3227	2.2
62	Plasma Cell Disorders in Patients with Age-Related Transthyretin (ATTRwt) Amyloidosis. *Blood*, **2018**, 132, 5610-5610	2.2
61	Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon, in Patients with Relapsed or Refractory Multiple Myeloma (MM), Acute Myeloid Leukemia (AML), and T-Cell Neoplasms (TCL). *Blood*, **2018**, 132, 3268-3268	2.2
60	Three Decades of Autologous Stem Cell Transplantation for Myeloma; Trends in Early Mortality and Survival. *Blood*, **2018**, 132, 3436-3436	2.2
59	Characterization of Exceptional Responders to Autologous Stem Cell Transplantation in Multiple Myeloma. *Blood*, **2018**, 132, 4615-4615	2.2
58	Patient-Reported Outcome Driven Case Management System for Hematology – a Prospective Study. *Blood*, **2018**, 132, 719-719	2.2
57	Outcomes of patients with light chain amyloidosis who had autologous stem cell transplantation with three or more organs involved.. *Journal of Clinical Oncology*, **2019**, 37, 8011-8011	2.2
56	Implications and outcomes of MRD-negative multiple myeloma patients with immunofixation positivity.. *Journal of Clinical Oncology*, **2019**, 37, 8034-8034	2.2
55	Delayed Neutrophil Engraftment in Patients Receiving Daratumumab As Part of Their First Induction Regimen for Multiple Myeloma. *Blood*, **2019**, 134, 4505-4505	2.2
54	Hypovitaminosis D Is Prevalent in Patients with Renal AL Amyloidosis and Associated with Non-t(11;14). *Blood*, **2019**, 134, 5523-5523	2.2
53	Waldenström Macroglobulinemia with Excess Plasma Cells: Is It a Distinct Entity?. *Blood*, **2019**, 134, 1532-1532	2.2
52	Metaphase Cytogenetics for Risk Stratification in Newly Diagnosed Multiple Myeloma. *Blood*, **2019**, 134, 4396-4396	2.2
51	Impact of sFLC Ratio on Outcome in Patients with MM: Validating the Utility of sFLC in Response Definition. *Blood*, **2019**, 134, 3080-3080	2.2
50	Determinants of Clinical Trial Participation and Impact on Survival Outcomes Among Patients with Newly Diagnosed Multiple Myeloma. *Blood*, **2019**, 134, 5833-5833	2.2
49	Phase 2 Trial of Ixazomib, Cyclophosphamide and Dexamethasone in Relapsed Multiple Myeloma. *Blood*, **2019**, 134, 1904-1904	2.2
48	Functional Interrogation of Variants of Undetermined Significance of the Isocitrate Dehydrogenase 1 and 2 Genes in Myeloid Neoplasms. *Blood*, **2019**, 134, 1697-1697	2.2

47	Increased Mean Corpuscular Volume Is an Independent Predictor for Worse Overall Survival in Patients with Newly Diagnosed Light Chain Amyloidosis. *Blood*, **2019**, 134, 5532-5532	2.2
46	The Impact of Socioeconomic Risk Factors on the Survival Outcomes of Patients with Newly Diagnosed Multiple Myeloma. *Blood*, **2019**, 134, 2197-2197	2.2
45	Prognostic role of beta-2 microglobulin in patients with light chain amyloidosis treated with autologous stem cell transplantation.. *Journal of Clinical Oncology*, **2020**, 38, e20506-e20506	2.2
44	Depth of response prior to autologous stem cell transplantation to predict survival in light chain amyloidosis.. *Journal of Clinical Oncology*, **2020**, 38, 8516-8516	2.2
43	Assessing the utility of monitoring IgA multiple myeloma patients with quantitative serum IgA levels.. *Journal of Clinical Oncology*, **2020**, 38, e20515-e20515	2.2
42	Pomalidomide Plus Low-Dose Dexamethasone (Pom/Dex) in Relapsed Lenalidomide Refractory Myeloma: Long Term Follow up and Comparison of 2 Mg Vs 4 Mg Doses. *Blood*, **2014**, 124, 4780-4780	2.2
41	Impact of Beta Blocker on Clinical Outcomes of Multiple Myeloma (MM) Patients. *Blood*, **2014**, 124, 4751-4751	2.2
40	Improvement in Renal Function and Its Impact on Survival in Patients with Newly Diagnosed Multiple Myeloma. *Blood*, **2014**, 124, 3368-3368	2.2
39	Estimating the Annual Volume of Hematologic Cancer Cases per Hematologist-Oncologist in the United States: Are We Treating Rare Cancers Too Rarely?. *Blood*, **2015**, 126, 3297-3297	2.2
38	Occurrence and Prognostic Significance of Cytogenetic Evolution in Patients with Multiple Myeloma. *Blood*, **2015**, 126, 4176-4176	2.2
37	Natural History of Amyloidosis Isolated to Fat and Bone Marrow Aspirate. *Blood*, **2015**, 126, 5303-5303	2.2
36	The Role of Spleen Directed Therapy and Predictors of Outcomes with Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Primary Myelofibrosis and Splenomegaly. *Blood*, **2015**, 126, 4370-4370	2.2
35	Prevalence and survival of smoldering multiple myeloma in the US: Analysis using a national dataset.. *Journal of Clinical Oncology*, **2016**, 34, 8035-8035	2.2
34	Changes in serum alkaline phosphatase levels to predict response to ixazomib-based therapy in patients with newly diagnosed multiple myeloma.. *Journal of Clinical Oncology*, **2016**, 34, 8053-8053	2.2
33	Clinical utility of the revised international staging system (RISS) in newly diagnosed multiple myeloma.. *Journal of Clinical Oncology*, **2016**, 34, 8017-8017	2.2
32	Type 1 monoclonal cryoglobulinemia: Clinical presentation and outcomes.. *Journal of Clinical Oncology*, **2016**, 34, 8062-8062	2.2
31	Immunoparesis in newly diagnosed AL amyloidosis as a marker for response and survival.. *Journal of Clinical Oncology*, **2016**, 34, 8016-8016	2.2
30	Clinical Presentation and Outcome of Patients with Myeloid Differentiation Factor 88 Gene (MYD88) Wild-Type Waldenstrom Macroglobulinemia. *Blood*, **2016**, 128, 2960-2960	2.2

29	Prognostic Implications of Multiple Cytogenetic High-Risk Abnormalities in Patients with Newly Diagnosed Multiple Myeloma. *Blood*, **2016**, 128, 5615-5615	2.2
28	Thyroid Functional Abnormalities in Newly Diagnosed AL Amyloidosis: Frequency and Influence By Type of Organ Involvement and Disease Burden. *Blood*, **2016**, 128, 3273-3273	2.2
27	Changes in Uninvolved Immunoglobulins during Multiple Myeloma Therapy. *Blood*, **2016**, 128, 3251-3251	2.2
26	Survival Trends in Young Patients with Waldenstrom Macroglobulinemia: Over 5 Decades of Experience. *Blood*, **2016**, 128, 1810-1810	2.2
25	Beta-Blockers Improved Survival Outcomes in Patients with Multiple Myeloma: A Retrospective Evaluation. *Blood*, **2016**, 128, 3306-3306	2.2
24	The Prognostic Significance of Polyclonal Bone Marrow Plasma Cells in Patients with Actively Relapsing Multiple Myeloma. *Blood*, **2016**, 128, 1194-1194	2.2
23	Fluorescence in-Situ Hybridization (FISH) Analysis in Untreated AL Amyloidosis Has an Independent Prognostic Impact By Abnormality Type and Treatment Category. *Blood*, **2016**, 128, 3269-3269	2.2
22	Treatment Patterns and Outcomes Following Initial Relapse in Patients with Relapsed Systemic Immunoglobulin Light Chain Amyloidosis. *Blood*, **2016**, 128, 3338-3338	2.2
21	Predicting Poor Overall Survival in Patients with Newly Diagnosed Multiple Myeloma and Standard-Risk Cytogenetics Treated with Novel Agents. *Blood*, **2016**, 128, 3255-3255	2.2
20	Outcome of Very Young (≤40 years) Patients with Immunoglobulin Light Chain Amyloidosis (AL): A Case Control Study. *Blood*, **2016**, 128, 5576-5576	2.2
19	Impact of Melphalan-Based Chemotherapy on Stem Cell Collection in Patients with Light Chain Amyloidosis. *Blood*, **2016**, 128, 2187-2187	2.2
18	Bortezomib, Melphalan and Low Dose TBI Conditioning for Patients Undergoing Autologous Stem Cell Transplantation for Multiple Myeloma. *Blood*, **2016**, 128, 2267-2267	2.2
17	The use of proteasome inhibitors among patients with POEMS syndrome.. *Journal of Clinical Oncology*, **2017**, 35, e19530-e19530	2.2
16	Outcomes according to involved free light chain (FLC) levels in patients with normal FLC ratio after initial therapy in light chain amyloidosis (AL).. *Journal of Clinical Oncology*, **2017**, 35, 8049-8049	2.2
15	Risk stratification by detection of clonal circulating plasma cells (CPCs) by multi-parametric flow cytometry (MFC) in light chain amyloidosis (AL).. *Journal of Clinical Oncology*, **2017**, 35, 8047-8047	2.2
14	Overuse of organ biopsies in immunoglobulin light chain (AL) amyloidosis: The consequence of failure of early recognition.. *Journal of Clinical Oncology*, **2017**, 35, e19532-e19532	2.2
13	Smoldering Waldenström macroglobulinemia (SWM): Analysis from the National Cancer Database (NCDB).. *Journal of Clinical Oncology*, **2017**, 35, 1573-1573	2.2
12	The impact of body mass index on the risk of early progression of smoldering multiple myeloma to symptomatic myeloma.. *Journal of Clinical Oncology*, **2017**, 35, 8032-8032	2.2

11	Treatment approaches and outcomes in extramedullary plasmacytomas.. *Journal of Clinical Oncology*, **2017**, 35, 8050-8050	2.2
10	Prognostic Value Of Quantifying Circulating Plasma Cells By Multiparametric Flow Cytometry In Patients With Relapsed Multiple Myeloma. *Blood*, **2013**, 122, 754-754	2.2
9	Extramedullary Leukemia Relapse In Patients With Acute Myeloid Leukemia Allogeneic Stem Cell Transplantation: Risk Factors and Prognosis. *Blood*, **2013**, 122, 2081-2081	2.2
8	Increased Circulating Plasma Cells On Multiparametric Flow Cytometry As An Independent Prognostic Biomarker In Newly Diagnosed Multiple Myeloma: Implications For Redefining High-Risk Myeloma. *Blood*, **2013**, 122, 1842-1842	2.2
7	Impact of stratifying levels of serum lactate dehydrogenase (LDH) at diagnosis on the overall survival (OS) in newly diagnosed multiple myeloma (NDMM).. *Journal of Clinical Oncology*, **2021**, 39, e20016-e20016	2.2
6	Functional evaluation of isocitrate dehydrogenase 1 and 2 variants of unclear significance in chronic myeloid neoplasms. *Leukemia Research*, **2019**, 87, 106264	2.7
5	Prognostic Implications of Rising Serum Monoclonal Protein and Free Light Chains after Autologous Stem Cell Transplantation in Patients with Multiple Myeloma. *Transplantation and Cellular Therapy*, **2021**, 27, 309.e1-309.e5	
4	Practical management and assessment of primary plasma cell leukemia in the novel agent era. *Cancer Treatment and Research Communications*, **2021**, 28, 100414	2
3	Success of the autologous stem cell boost after autologous graft failure in multiple myeloma and AL amyloidosis.. *Bone Marrow Transplantation*, **2022**,	4.4
2	Estimation of Kidney Function in Patients With Multiple Myeloma: Implications for Lenalidomide Dosing.. *Annals of Pharmacotherapy*, **2022**, 10600280221087218	2.9
1	Patient Experience in Clinical Trials: Quality of Life, Financial Burden, and Perception of Care in Patients With Multiple Myeloma or Lymphoma Enrolled on Clinical Trials Compared With Standard Care.. *JCO Oncology Practice*, **2022**, OP2100789	2.3